- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04984785
Lipid Metabolism in Obese Subjects Undergoing Bariatric Surgery
July 28, 2021 updated by: Sebastiano Banni, University of Cagliari
Characterization of Physiological Mechanisms Involved in the Regulation of Eating Behavior for the Identification of Innovative Nutritional Strategies for Obese Patients Before and After Bariatric Surgery
The aim of the study is to evaluate modifications in the metabolism of polyunsaturated fatty acids (PUFA) and biosynthesis of the lipid mediators N-acylethanolamines (NAE), both known to induce and be induced by the nuclear peroxisome proliferator-activated receptor (PPAR)-α, which may also explain the well-established improved lipid and energy metabolism after bariatric surgery.
The study is focused on understanding the weight loss mechanisms in order to develop targeted dietary protocols.
Study Overview
Status
Completed
Detailed Description
The study involves a careful preliminary medical history of the patients, with physical examination, anthropometric parameters measurements and blood sampling for blood chemistry routine and evaluation of any adverse events to assess suitability for the study.
The evening before bariatric surgery, one month and six months after bariatric surgery anthropometric parameters measurements, blood sampling for blood chemistry routine, inflammatory and lipid-metabolomic profile, and evaluation of any adverse events are performed.
For the study samples are stored identified by a code to be analyzed anonymously.
Study interruption criteria are: development of allergic reactions, ketonemia> 1.5 mmol/L, acute gout
Study Type
Observational
Enrollment (Actual)
68
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cagliari, Italy
- Centro di Chirurgia Bariatrica dell'Azienda Ospedaliera G. Brotzu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients eligible for bariatric surgery
Description
Inclusion Criteria:
- subjects with pathological obesity suitable for bariatric surgery
- Body Mass Index (BMI) range 35-59
Exclusion Criteria:
- established diagnoses of a major disease (e.g., diabetes or kidney disease)
- pregnancy or breastfeeding,
- food allergies,
- use of drugs that could affect lipid metabolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modifications of Endocannabinoid and N-acylethanolamine plasma levels
Time Frame: 6 months
|
These lipid derivatives are involved in control of energy expenditure and lipid metabolism and are measured by LC MS/MS and expressed as nmol/ml plasma
|
6 months
|
|
Weight loss as kg, and fat mass reduction as total kg and percent of body mass
Time Frame: 6 months
|
Indicators of the success of the intervention
|
6 months
|
|
Changes in fatty acid plasma profile induced by bariatric surgery
Time Frame: 6 months
|
Fatty acid profile affect lipid derivatives.
Fatty acid are measured by LC and GC and expressed as nmol/ml plasma
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sebastiano Banni, PhD, Università di Cagliari
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2019
Primary Completion (Actual)
November 4, 2019
Study Completion (Actual)
September 7, 2020
Study Registration Dates
First Submitted
May 31, 2021
First Submitted That Met QC Criteria
July 28, 2021
First Posted (Actual)
August 2, 2021
Study Record Updates
Last Update Posted (Actual)
August 2, 2021
Last Update Submitted That Met QC Criteria
July 28, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- unica
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.